AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9412611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 9412611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 721
Study 8504976 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatin
Number of subjects: 17
Study 8504976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2894247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol injections
Number of subjects: 28
Study 2894247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing colforsin (forskolin), aminophylline, and yohimbine
Number of subjects: 28
Study 2894247 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine cream
Number of subjects: 28
Study 2894247 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin cream
Number of subjects: 28
Study 2894247 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline cream
Number of subjects: 28
Study 2894247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injection or cream)
Number of subjects: 28
Study 29465629 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium fasteners
Number of subjects: 73
Study 29465629 — intervention group
Group type: COMPARATOR
Intervention: Hand-tied knots
Number of subjects: 73
Study 27018897 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Decision Aid + Health Coaching (DA+HC)
Number of subjects: 199
Study 27018897 — intervention group
Group type: COMPARATOR
Intervention: Video Decision Aid only (DA)
Number of subjects: 199
Study 24059730 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGT6 (six-session palmtop computer-assisted Group CBT)
Number of subjects: 34
Study 24059730 — intervention group
Group type: COMPARATOR
Intervention: CBGT6 (six-session Group CBT without the computer)
Number of subjects: 34
Study 24059730 — intervention group
Group type: COMPARATOR
Intervention: CBGT12 (typical 12-session Group CBT)
Number of subjects: 34
Study 24059730 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGT6
Number of subjects: 34
Study 22841478 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of virus protein per 0.5 mL formulation
Number of subjects: 370
Study 22841478 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg of virus protein per 0.5 mL formulation
Number of subjects: 370
Study 22841478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 μg of virus protein per 0.5 mL formulation
Number of subjects: 370
Study 20353659 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Nudge electronic reminders
Number of subjects: 38000
Study 20353659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38000
Study 18688013 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/h clazosentan
Number of subjects: 413
Study 18688013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/h clazosentan
Number of subjects: 413
Study 18688013 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/h clazosentan
Number of subjects: 413
Study 18688013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 16187967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide 5' mono-nitrate (ISMN) 120 mg
Number of subjects: 34
Study 16187967 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (TD-NTG) 15 mg 24 h(‐1)
Number of subjects: 34
Study 16187967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) 10 micromol l(‐1)
Number of subjects: 34
Study 16187967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (NTG) 100 micromol l(‐1)
Number of subjects: 34
Study 16187967 — intervention group
Group type: COMPARATOR
Intervention: ADP (1 micromol l(‐1))
Number of subjects: 34
Study 12773674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid MR imaging
Number of subjects: 88
Study 12773674 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 88
Study 12773674 — intervention group
Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 88
Study 10950384 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C (PVE corrected rCBF during rest)
Number of subjects: 8
Study 10950384 — intervention group
Group type: COMPARATOR
Intervention: Autoradiographic method (2D acquisition)
Number of subjects: 8
Study 10950384 — intervention group
Group type: COMPARATOR
Intervention: Autoradiographic method (3D acquisition)
Number of subjects: 8
Study 10950384 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C and D (activation response)
Number of subjects: 8
Study 10950384 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C (activation response)
Number of subjects: 8
Study 8840095 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 10
Study 8840095 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 10
Study 1993133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase 1.5 x 10(6) IU (n = 55)
Number of subjects: 81
Study 1993133 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (n = 26)
Number of subjects: 81
Study 6687717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 6687717 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 31985129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week nurse-led transitional care intervention based on the Omaha System
Number of subjects: 88
Study 31985129 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 88
Study 31288213 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR‐RT at 30% 1RM
Number of subjects: 28
Study 31288213 — intervention group
Group type: COMPARATOR
Intervention: HL‐RT at 70% 1RM
Number of subjects: 28
Study 28079606 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based care
Number of subjects: 628
Study 28079606 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 628
Study 25487798 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (oral-i.v. combination)
Number of subjects: 61
Study 25487798 — intervention group
Group type: COMPARATOR
Intervention: GSK1322322 (i.v. only)
Number of subjects: 61
Study 25487798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24052491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, short-duration dietary oral supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 0
Study 24052491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21636820 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 12
Study 21636820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Number of subjects: 12
Study 21636820 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 19151300 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 66
Study 19151300 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 66
Study 16510634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0
Study 16510634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0
Study 16510634 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and nonsurgical interventions
Number of subjects: 0
Study 16510634 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (clinical examination or ultrasound)
Number of subjects: 0
Study 11812666 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis administration in supine position
Number of subjects: 30
Study 11812666 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis administration in supine position with leg elevation
Number of subjects: 30
Study 11812666 — intervention group
Group type: COMPARATOR
Intervention: Leg elevation in pre-digitalis state (normal ventricular function)
Number of subjects: 30
Study 11812666 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg elevation in LVD patients
Number of subjects: 30
Study 11812666 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis administration in LVD patients
Number of subjects: 30
Study 10409470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg intravenously pre-operatively
Number of subjects: 12
Study 10409470 — intervention group
Group type: COMPARATOR
Intervention: No pamidronate (control group)
Number of subjects: 12
Study 7582139 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 100
Study 7582139 — intervention group
Group type: COMPARATOR
Intervention: Mail follow-up
Number of subjects: 100
Study 7582139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for follow-up
Number of subjects: 100
Study 2147517 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine (30 mg/day)
Number of subjects: 40
Study 2147517 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline (150 mg/day)
Number of subjects: 40
Study 390784 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 20
Study 390784 — intervention group
Group type: COMPARATOR
Intervention: High-dose steroids
Number of subjects: 20
Study 6614412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 20
Study 6614412 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study 30145124 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-positive group (n=13)
Number of subjects: 28
Study 30145124 — intervention group
Group type: COMPARATOR
Intervention: MRI-negative group (n=15)
Number of subjects: 28
Study 29290087 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy with mild hydronephrosis (Group C)
Number of subjects: 371
Study 29290087 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure shock wave lithotripsy (Group A)
Number of subjects: 371
Study 29290087 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy in prone position (Group B)
Number of subjects: 371
Study 29290087 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 371
Study 27521810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (100mg/day)
Number of subjects: 331
Study 27521810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 25326208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy (HA)
Number of subjects: 0
Study 25326208 — intervention group
Group type: COMPARATOR
Intervention: Short format of health scenarios
Number of subjects: 0
Study 25326208 — intervention group
Group type: COMPARATOR
Intervention: Long format of health scenarios
Number of subjects: 0
Study 23106853 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U)
Number of subjects: 621
Study 20308718 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 75
Study 20308718 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 75
Study 17631071 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 501
Study 16172700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (0.25 to 0.50 mg/kg for three months)
Number of subjects: 32
Study 16172700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12441944 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact laser therapy
Number of subjects: 340
Study 12441944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostate resection
Number of subjects: 340
Study 12441944 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 340
Study 10096264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice a day)
Number of subjects: 20
Study 10096264 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (standard treatment for high blood pressure)
Number of subjects: 20
Study 7577202 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin and cytarabine with granulocyte colony-stimulating factor (G-CSF) as supportive care
Number of subjects: 0
Study 7577202 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine without granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 2013680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with a maintenance dose of 1.94 micrograms of antigen E (Amb a I) for 8 months (total dose equivalent to 24 micrograms of antigen E)
Number of subjects: 21
Study 2013680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 21
Study 2013680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6756509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen + Immunotherapy
Number of subjects: 318
Study 6756509 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Immunotherapy
Number of subjects: 318
Study 6756509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 318
Study 31924377 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide-resistant Mycoplasma pneumoniae
Number of subjects: 826
Study 31924377 — intervention group
Group type: COMPARATOR
Intervention: Macrolide-susceptible Mycoplasma pneumoniae
Number of subjects: 826
Study 31924377 — intervention group
Group type: EXPERIMENTAL
Intervention: MLVA 4-5-7-2
Number of subjects: 826
Study 31924377 — intervention group
Group type: EXPERIMENTAL
Intervention: MLVA 4-5-7-3
Number of subjects: 826
Study 31924377 — intervention group
Group type: EXPERIMENTAL
Intervention: MLVA 1-5-6-2
Number of subjects: 826
Study 30563829 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (3 mg orally daily)
Number of subjects: 0
Study 30563829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29218705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid AED taper (30% to 50% dose reduction)
Number of subjects: 140
Study 29218705 — intervention group
Group type: COMPARATOR
Intervention: Slow AED taper (15% to <30% dose reduction)
Number of subjects: 140
Study 29218705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid AED taper
Number of subjects: 140
Study 29218705 — intervention group
Group type: COMPARATOR
Intervention: Slow AED taper
Number of subjects: 140
Study 27333978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with negative ΔQRS (persistent electrical dyssynchrony)
Number of subjects: 95
Study 27333978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with persistent electrical dyssynchrony (ED)
Number of subjects: 95
Study 27333978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with negative ΔQRS
Number of subjects: 95
Study 27333978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with QRS prolongation
Number of subjects: 95
Study 24754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological attributions
Number of subjects: 220
Study 24754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal responsibility attributions
Number of subjects: 220
Study 24754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Food environment attributions
Number of subjects: 220
Study 24754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Food environment information (Study 2)
Number of subjects: 220
Study 21997197 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 2 injections of 1.25 mg with 6-week intervals
Number of subjects: 105
Study 21997197 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab combined with triamcinolone (IVB/IVT) - 1.25 mg of IVB with 2 mg of IVT
Number of subjects: 105
Study 21997197 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 mg of IVT
Number of subjects: 105
Study 19648218 — intervention group
Group type: EXPERIMENTAL
Intervention: R231857
Number of subjects: 42
Study 19648218 — intervention group
Group type: EXPERIMENTAL
Intervention: R231857 with scopolamine
Number of subjects: 42
Study 19648218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19648218 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 42
Study 17665231 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (monotherapy)
Number of subjects: 304
Study 17665231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (monotherapy)
Number of subjects: 304
Study 17665231 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine (monotherapy)
Number of subjects: 304
Study 17665231 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (monotherapy)
Number of subjects: 304
Study 16224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic extended right hemicolectomy plus lymphadenectomy with skeletonization
Number of subjects: 30
Study 16224654 — intervention group
Group type: COMPARATOR
Intervention: Open extended right hemicolectomy plus lymphadenectomy with skeletonization
Number of subjects: 30
Study 12098725 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 315
Study 12098725 — intervention group
Group type: COMPARATOR
Intervention: Delayed antibiotics
Number of subjects: 315
Study 10463975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin
Number of subjects: 31
Study 8647061 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (WHF)
Number of subjects: 80
Study 8647061 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy collagen hydrolysate formula (SCHF)
Number of subjects: 80
Study 8647061 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-casein hydrolysate formula (WCHF)
Number of subjects: 80
Study 8647061 — intervention group
Group type: COMPARATOR
Intervention: Whey predominant hydrolysed preterm formulas
Number of subjects: 80
Study 8647061 — intervention group
Group type: COMPARATOR
Intervention: All three protein hydrolysate formulas
Number of subjects: 80
Study 8647061 — intervention group
Group type: EXPERIMENTAL
Intervention: Some hydrolysate formulas
Number of subjects: 80
Study 2113036 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (Study group)
Number of subjects: 18
Study 2113036 — intervention group
Group type: COMPARATOR
Intervention: Standard Rose's formula (Control group)
Number of subjects: 18
Study 468450 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipid meal
Number of subjects: 6
Study 468450 — intervention group
Group type: COMPARATOR
Intervention: High protein meal
Number of subjects: 6
Study 468450 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate meal
Number of subjects: 6
Study 28277430 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrepetition rest design
Number of subjects: 17
Study 28277430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster design
Number of subjects: 17
Study 28277430 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional design
Number of subjects: 17
Study 28421677 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR (8 weekly group sessions of MBSR)
Number of subjects: 166
Study 28421677 — intervention group
Group type: COMPARATOR
Intervention: Active controls (self-instructing MBSR)
Number of subjects: 166
Study 28421677 — intervention group
Group type: COMPARATOR
Intervention: Non-MBSR
Number of subjects: 166
Study 25944411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31
Study 25944411 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31
Study 25944411 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet counselling only)
Number of subjects: 31
Study 25944411 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of zoledronate (5 mg administered intravenously) plus diet counselling
Number of subjects: 31
Study 23351627 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-serving label format
Number of subjects: 9493
Study 23351627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-column label format
Number of subjects: 9493
Study 23351627 — intervention group
Group type: COMPARATOR
Intervention: Single column label format with 2 servings
Number of subjects: 9493
Study 21317630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered quitline intervention
Number of subjects: 300
Study 21317630 — intervention group
Group type: COMPARATOR
Intervention: Control standard brief stop-smoking intervention
Number of subjects: 300
Study 21317630 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline intervention
Number of subjects: 300
Study 18218053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 52
Study 18218053 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy frameworks
Number of subjects: 52
Study 16484504 — intervention group
Group type: EXPERIMENTAL
Intervention: High trough concentration (10‐15 ng/ml) group (HT group)
Number of subjects: 63
Study 16484504 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 63
Study 12920610 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid for 15 s
Number of subjects: 0
Study 12920610 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid for 15 s and 5% sodium hypochlorite for 2 min
Number of subjects: 0
Study 12920610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite for 5 min
Number of subjects: 0
Study 12920610 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 0
Study 10740552 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 50
Study 10740552 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 50
Study 8633831 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycoside dosing
Number of subjects: 13
Study 8633831 — intervention group
Group type: COMPARATOR
Intervention: Standard aminoglycoside regimens
Number of subjects: 13
Study 1421050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol 200 mg commercial tablets
Number of subjects: 34